![Foto de José Luis](/img/uploaded/68852BA5476E9B415AAE0740BEE25B4A.jpg)
José Luis
Ordóñez García
Profesor Permanente Laboral
Publicaciones (35) Publicaciones de José Luis Ordóñez García
2023
-
Renal Sympathetic Hyperactivity in Diabetes Is Modulated by 5-HT1D Receptor Activation via NO Pathway
International Journal of Molecular Sciences, Vol. 24, Núm. 2
2022
-
CRISPR/Cas9‐Directed Gene Trap Constitutes a Selection System for Corrected BCR/ABL Leukemic Cells in CML
International Journal of Molecular Sciences, Vol. 23, Núm. 12
2021
-
Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression
Blood Cancer Journal, Vol. 11, Núm. 7
-
CRISPR-Cas9 Technology as a Tool to Target Gene Drivers in Cancer: Proof of Concept and New Opportunities to Treat Chronic Myeloid Leukemia
CRISPR Journal, Vol. 4, Núm. 4, pp. 519-535
-
Dissecting the role of TP53 alterations in del(11q) chronic lymphocytic leukemia
Clinical and Translational Medicine, Vol. 11, Núm. 2
2020
-
CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition
Leukemia, Vol. 34, Núm. 6, pp. 1599-1612
-
ETV6/RUNX1 Fusion Gene Abrogation Decreases the Oncogenicity of Tumour Cells in a Preclinical Model of Acute Lymphoblastic Leukaemia
Cells, Vol. 9, Núm. 1
2019
-
Preclinical efficacy of endoglin-targeting antibody–drug conjugates for the treatment of Ewing sarcoma
Clinical Cancer Research, Vol. 25, Núm. 7, pp. 2228-2240
2017
-
Correction: The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin [Oncotarget, 6, (2015), (18875-18890)]. doi: 10.18632/oncotarget.4303
Oncotarget
-
The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of BCR/ABL in vitro and in a xenograft model of chronic myeloid leukemia
Oncotarget, Vol. 8, Núm. 16, pp. 26027-26040
2016
-
Molecular pathology of bone and soft tissue tumors
The Molecular Basis of Human Cancer (Springer New York), pp. 623-655
-
Proteomic Profiling of Ewing Sarcoma Reveals a Role for TRAF6 in Proliferation and Ribonucleoproteins/RNA Processing
Journal of Proteomics & Bioinformatics, Vol. 09, Núm. 06
2015
-
Molecular Genetics of Ewing Sarcoma
eLS, pp. 1-11
-
The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin
Oncotarget, Vol. 6, Núm. 22, pp. 18875-18890
-
Trabectedin efficacy in Ewing sarcoma is greatly increased by combination with anti-IGF signaling agents
Clinical Cancer Research, Vol. 21, Núm. 6, pp. 1373-1382
2014
-
Characterization of human mesenchymal stem cells from Ewing sarcoma patients. Pathogenetic implications
PLoS ONE, Vol. 9, Núm. 2
-
Innovative therapies in ewing sarcoma
Advances in Anatomic Pathology, Vol. 21, Núm. 1, pp. 44-62
2013
-
Fluorescence in situ hybridization analysis of CCND3 gene as marker of progression in bladder carcinoma
Journal of Biological Regulators and Homeostatic Agents, Vol. 27, Núm. 2, pp. 559-567
-
The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis
Carcinogenesis, Vol. 34, Núm. 2, pp. 268-276
-
WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells
Oncogene, Vol. 32, Núm. 11, pp. 1441-1451